N01372 AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY

Grants and Contracts Details

StatusFinished
Effective start/end date8/15/136/30/15

Funding

  • UCB Pharma (domestic): $3,000.00